These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 2499564)
1. In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach. Martin MA; Pfaller MA; Rojas PB; Woolson RF; Wenzel RP J Antimicrob Chemother; 1989 Mar; 23(3):353-61. PubMed ID: 2499564 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Doebbeling BN; Pfaller MA; Bale MJ; Wenzel RP Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):298-301. PubMed ID: 2112467 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients. Díez-Aguilar M; Ekkelenkamp M; Morosini MI; Merino I; de Dios Caballero J; Jones M; van Westreenen M; Tunney MM; Cantón R; Fluit AC Int J Antimicrob Agents; 2019 Jan; 53(1):84-88. PubMed ID: 30240837 [TBL] [Abstract][Full Text] [Related]
5. N-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics. Martino P; Venditti M; Valente B; Brandimarte C; Serra P Drugs Exp Clin Res; 1985; 11(4):247-51. PubMed ID: 3939121 [TBL] [Abstract][Full Text] [Related]
6. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862 [TBL] [Abstract][Full Text] [Related]
7. Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency. Stanley GL; Pfaller MA; Mori M; Wenzel RP J Hosp Infect; 1989 Oct; 14(3):217-25. PubMed ID: 2575103 [TBL] [Abstract][Full Text] [Related]
8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China. Chen H; Wang Z; Li H; Wang Q; Zhao C; He W; Wang X; Zhang F; Wang H Jpn J Infect Dis; 2015; 68(4):263-7. PubMed ID: 25672407 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials. Matsuyama JR; Beail B; Wallis C; Zeleznik D; Tartaglione T Clin Pharm; 1991 Jul; 10(7):544-8. PubMed ID: 1860303 [TBL] [Abstract][Full Text] [Related]
11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)]. Zarakolu P; Hasçelik G; Unal S Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
14. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China]. Chen MJ; Wang H; Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912 [TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients. Rolston KV; LeBlanc B; Ho DH; Bodey GP J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445 [TBL] [Abstract][Full Text] [Related]
16. Comparative in-vitro activity of the penem FCE 22101 against recent European blood culture isolates. Dornbusch K; Kronvall G; Göransson E; Mörtsell E J Antimicrob Chemother; 1989 Mar; 23 Suppl C():43-52. PubMed ID: 2732143 [TBL] [Abstract][Full Text] [Related]
17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Fujime M; Fujita K; Hirose T; Matsukawa M; Takahashi S; Kunishima Y; Igari J; Ogihara M; Ishibashi K; Oguri T; Shigeta S; Yamaguchi K; Matsumoto T; Kashitani F; Yoshida H; Imafuku Y; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Kitamura M; Takano Y; Matsuoka Y; Matsuda S; Sato S; Furuhama T; Kumon H; Monden K; Aoki S; Mochida C; Hirakata Y; Kohno S; Miyazaki Y; Tomono K Jpn J Antibiot; 2002 Aug; 55(4):370-98. PubMed ID: 12378869 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Sutherland CA; Nicolau DP Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525 [TBL] [Abstract][Full Text] [Related]
19. Activity of ceftazidime against Gram-negative bacilli from paediatric patients. Nelson JD; Shelton S J Antimicrob Chemother; 1981 Sep; 8 Suppl B():179-81. PubMed ID: 19802983 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. Pillar CM; Aranza MK; Shah D; Sahm DF J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]